The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...

"We are figuring out ways that AI can make that faster and cheaper." One of the major challenges in pharmaceutical medicine development is understanding not only how a drug might affect the body ...

End-to-end automation could offer significant benefits: speed, accuracy, and scalability. Digital workers perform repetitive ...

Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

One of the most promising aspects of AI and its integration into the pharmaceutical industry is the technology’s potential to discover new molecules and potential therapies. Pfizer is partnering with ...

Simulations Plus excels in AI-driven biosimulation but faces margin erosion. Find out why SLP stock warrants a hold rating ...

Even still, the pharma deals announced out of the event brought a clear message for the biotech industry. Technology ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

SandboxAQ, a startup drawing on quantum computing techniques to develop quantitative artificial intelligence models for ...